Clinical Trial

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with high tumour mutation burden
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-10-21; most recent amendment 2026-06-16.
Status change: Not Yet Recruiting → Recruiting 2025-09-16
Trial Details
NCT Number NCT05093231
Lead Sponsor Cambridge University Hospitals NHS Foundation Trust
Collaborators: National Institute for Health Research, United Kingdom
Conditions Pancreatic Cancer
Enrollment 20 participants
Start Date 2025-02-26
Primary Completion 2027-07-31 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-17